NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 493 shares, a decline of 73.5% from the December 15th total of 1,861 shares. Based on an average trading volume of 628 shares, the short-interest ratio is presently 0.8 days. Based on an average trading volume of 628 shares, the short-interest ratio is presently 0.8 days.
Hedge Funds Weigh In On NewAmsterdam Pharma
An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC raised its position in shares of NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) by 1.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,000 shares of the company’s stock after acquiring an additional 3,043 shares during the period. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
NewAmsterdam Pharma Stock Up 3.7%
Shares of NAMSW traded up $0.85 during midday trading on Tuesday, hitting $23.95. 400 shares of the company traded hands, compared to its average volume of 300. The firm has a 50 day moving average of $25.92 and a 200-day moving average of $19.18. NewAmsterdam Pharma has a 52 week low of $5.45 and a 52 week high of $29.99.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.
The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.
Featured Stories
- Five stocks we like better than NewAmsterdam Pharma
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- This stock gets a 94 out of 100
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
